Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.

ABSTRACT:

Background

Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.

Objectives

This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.

Methods

This retrospective single-center study identified stage I-III NSCLC patients with rare targetable mutations who underwent curative surgery. Tissue-based molecular profiling identified mutations in KRAS</

SUBMITTER: Ghazali N 

PROVIDER: S-EPMC11672496 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature